Lupin gets USFDA nod for hypertension treatment drug in US

Drug major Lupin has received tentative approval from the US health regulator to sell Olmesartan medoximil tablets, used for treating high blood pressure, in the American market.

"It has received tentative (rpt) tentative approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA)," Lupin said in a BSE filing on Monday.

Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure, it added.

ALSO READ: Lupin gets USFDA approval for generic Alzheimer treatment capsule

Quoting IMS MAT September 2016 sales data, Lupin further said that Benicar tablets had annual US sales of $1.06 billion.

See LIVE stock updates of Lupin here-

On Monday, the stock of Lupin closed down 2.78% or Rs 40.25 at Rs 1,405.10 on BSE. 

ALSO READ: Lupin shares fall 2% despite receiving approval for Acotiamide tablets